Financing Round Co-led by Catalys Pacific and SR One, Investment to Drive the Development of Sparsentan for IgA Nephropathy in Japan and Other Asian Countries TOKYO, July 17, 2024 /PRNewswire/ — Renalys Pharma, Inc., a late-stage clinical biopharmaceutical company has completed a ¥6.0Bn…